Clinical Trial Update: A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD [Phase 4]

View source ↗

Summary

This completed Phase 4 multicenter trial evaluated the safety and efficacy of lobeglitazone for decreasing intrahepatic fat contents in people with type 2 diabe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Lobeglitazone (lobeglitazone)

Snippet

Sponsor: Yonsei University | Conditions: Type 2 Diabetes, Non-alcoholic Fatty Liver Disease | Phase 4 | Status: COMPLETED